In Hepatobiliary Disorders
Ursodeoxycholic Acid 150 mg
Improves absorption, bioavailability, and drug exposure by maintaining optimal pH for better pharmacokinetics
- FDA-approved ursodiol indicated for the treatment of primary biliary cholangitis.
- Strong choleretic action, with improved excretion rates and reduced bile acid transit time.
- Delivers a 59.4% response rate at 12 months, while slowing disease progression.
- Promotes liver health by increasing beneficial bile acids from less than 2% to about 65%.
- Complete relief of pruritus with reduced fetal distress and premature birth risk in ICP pregnancies.
Dosage (Adults)
10-15 mg/kg in 2 to 4 divided dosage preferably after meals
Indications:
- Primary Biliary Cholangitis
- Intrahepatic Cholestasis of Pregnancy (ICP)
- Gallbladder Stones
- Non Alcoholic Steato-hepatitis (NASH)
